010DS-Zn

N/A

Report date: 2025/01/26 19:21:14
NME

Base Information

Drug Name010DS-Zn
Drug Alias NameC010DS-Znonco-parthanatos immunotherapy (Xylonix)010DS-Zn (Xylonix)PARP modulator (Xylonix)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase modulatorsCluster of differentiation 8 stimulantsT-cell surface antigen CD4 agonists
TargetsPoly (ADP-Ribose) polymeraseCluster of differentiation 8T-cell surface antigen CD4
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursHeart Injuries +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesXylonix Pte Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXylonix Pte Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursHeart Injuries +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A